Least burdensome
This article was originally published in The Gray Sheet
Executive Summary
Appeals of decisions by FDA's Office of Device Evaluation are best addressed to the branch chief, deputy director, or director of the appropriate review division, FDA and the Least Burdensome Industry Task Force recommend in a July 31 document. If "least burdensome" disputes are still unresolved, a firm may contact the ODE program operations staff, and if necessary, file an appeal under 21 CFR 10.75 with the ODE director. While the document suggests that the Center for Devices and Radiological Health ombudsman be contacted after a formal appeal fails, it notes that the ombudsman may be contacted at any point in the process. In addition to deficiency letters, the appeals mechanism may be used if any "aspect of a guidance document poses an inappropriate burden"
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.